Stockscreener 앱 받기
6.38
3.79%
-0.22
전일 마감가:
$6.60
열려 있는:
$6.74
하루 거래량:
42,832
Relative Volume:
2.44
시가총액:
$26.16M
수익:
-
순이익/손실:
$-24.77M
주가수익비율:
-8.7397
EPS:
-0.73
순현금흐름:
$-17.36M
1주 성능:
-34.88%
1개월 성능:
+0.79%
6개월 성능:
-31.28%
1년 성능:
-25.22%
1일 변동 폭
$6.10
$7.21
1주일 범위
$4.5601
$9.80
52주 변동 폭
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
INKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
6.44 | 26.16M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.84 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.13 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.98 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Mink Therapeutics stock hits 52-week high at $8.84 By Investing.com - Investing.com Canada
MiNK Therapeutics announces reverse stock split - MSN
MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th - Defense World
MiNK Therapeutics, Inc. Announces a Presentation at the American Society of Clinical Oncology Gastrointestinal Cancers - Marketscreener.com
MiNK Therapeutics presents cancer study at ASCO GI - Investing.com India
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - The Manila Times
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics announces reverse stock split By Investing.com - Investing.com UK
Kinaxis Inc. (TSE:KXS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
MiNK Therapeutics (NASDAQ:INKT) vs. Evaxion Biotech A/S (NASDAQ:EVAX) Head to Head Analysis - Defense World
Nerdy, Inc. (NYSE:NRDY) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Stock Market Movers Today • Top Gainers & Losers - Benzinga
MML Investors Services LLC Acquires Shares of 12,147 Sabre Co. (NASDAQ:SABR) - Defense World
Carbon Streaming (OTCMKTS:OFSTF) Stock Price Up 5.5% – What’s Next? - Defense World
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire
Claire's Place Foundation Wraps up 2024 with Record-Breaking Events & Exciting Announcements for 2025 - The Manila Times
Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges - Investing.com Australia
Mink Ventures Commences Diamond Drill Program at Warren Nickel Copper Cobalt Project, Timmins, Ontario - Yahoo Finance
ATEX Resources (OTCMKTS:ECRTF) Stock Price Down 0.7% – Here’s Why - Defense World
Domo’s (DOMO) Market Outperform Rating Reiterated at JMP Securities - Defense World
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering - BioSpace
Arovella heads toward clinic with CAR-19-iNKT cells - BioWorld Online
Comparing MiNK Therapeutics (NASDAQ:INKT) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Geenex Developed Mink Solar Project Approved by Ohio Power Siting Board - Yahoo Finance
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Midwest Energy Emissions Becomes Birchtech Corp. and Announces Equity Incentive Plan AmendmentsOn October 29, 2024, Birchtech Corp. (formerly Midwest Energy Emissions Corp.) filed a Form 8-K with the SEC, detailing recent corporate changes and u - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
Mink Ventures Receives $89,160 in Non-Dilutive Capital With OJEP Grant for Warren Nickel Copper Cobalt Project - Yahoo Finance
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):